Small molecule APOL1 inhibitors as a precision medicine approach for APOL1-mediated kidney disease
Barry J. Zimmerman(Vertex Pharmaceuticals (United States)), Mark E. Bunnage(Vertex Pharmaceuticals (United States))
Cited by 18
Related Papers
The promise and peril of chemical probes
|Nature Chemical Biology|2015|848
Late-Stage Neuropsychiatric Lyme Borreliosis
|Psychosomatics|1995|41